13F-HR filed by VHCP Management, LLC
VHCP Management, LLC filed this 13F-HR for the quarter ended 2016-06-30, filed 2016-08-12, with 23 holding rows worth $96,495,000.
- Accession
- 0000950123-16-019779
- Filer
- CIK 1479355
- Filed
- 2016-08-12
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2016
A holdings report, 23 entries on the cover page, a total value of $96,495,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $96,495,000 with VALUE read as thousands by filing date, 13F file number 028-14329. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| DBV Technologies | F2927N109 | COM | 456,893 | $29,114,000 | thousands by filing date | |
| HERON THERAPEUTICS INC | 427746102 | COM | 1,095,734 | $19,778,000 | thousands by filing date | |
| COHERUS ONCOLOGY INC | 19249H103 | COM | 611,010 | $10,320,000 | thousands by filing date | |
| FLAMEL TECHNOLOGIES-SP ADR | 338488109 | SPON | 500,000 | $5,370,000 | thousands by filing date | |
| ZAFGEN INC | 98885E103 | COM | 602,114 | $3,607,000 | thousands by filing date | |
| Adverum Biotechnologies, Inc. | 00773U108 | Common Stock | 1,102,735 | $3,485,000 | thousands by filing date | |
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 1,005,104 | $2,854,000 | thousands by filing date | |
| Alcobra Ltd | M2239P109 | SHS | 623,313 | $2,799,000 | thousands by filing date | |
| LIPOCINE INC NEW | 53630X104 | CMN | 849,921 | $2,584,000 | thousands by filing date | |
| AXOVANT SCIENCES LTD | G0750W104 | COM | 184,110 | $2,364,000 | thousands by filing date | |
| AKARI THERAPEUTICS PLC | 00972G108 | ADR | 158,352 | $2,136,000 | thousands by filing date | |
| Cynapsus Therapeutics Inc | 23257Y701 | COM | 108,575 | $1,806,000 | thousands by filing date | |
| BEONE MEDICINES LTD SPONSORED ADS | 07725L102 | ADR | 51,000 | $1,520,000 | thousands by filing date | |
| OCERA THERAPEUTICS INC COM | 67552A108 | COM | 796,550 | $1,513,000 | thousands by filing date | |
| EDGE THERAPEUTICS INC | 279870109 | COM | 135,000 | $1,365,000 | thousands by filing date | |
| ARCA biopharma Inc | 00211Y100 | COM | 462,399 | $1,341,000 | thousands by filing date | |
| GLOBAL BLOOD THERAPEUTICS USD | 37890U108 | COM | 72,990 | $1,211,000 | thousands by filing date | |
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 90,000 | $1,194,000 | thousands by filing date | |
| STEMLINE THERAPEUTICS INC | 85858C107 | COM | 135,420 | $917,000 | thousands by filing date | |
| CYTOMX THERAPEUTICS INC | 23284F105 | COMMON STOCK | 64,200 | $656,000 | thousands by filing date | |
| REGENXBIO INC | 75901B107 | COM | 52,500 | $420,000 | thousands by filing date | |
| Sierra Oncology, Inc. | 74346L101 | common | 56,056 | $112,000 | thousands by filing date | |
| AEGLEA BIOTHERAPEUTICS INC | 00773J103 | COM | 6,000 | $29,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-16-019779 | this filing | 2016-08-12 | acceptance time not in the bulk data set |